A Phase 2, Open-label, Drug-Drug Interaction Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout

Trial Profile

A Phase 2, Open-label, Drug-Drug Interaction Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Arhalofenate (Primary) ; Colchicine; Febuxostat
  • Indications Gout; Hyperuricaemia
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors CymaBay Therapeutics
  • Most Recent Events

    • 15 Dec 2016 Primary endpoint (Proportion of patients achieving a target sUA 4.0 on Day 29 after treatment with arhalofenate 800 mg and febuxostat 80 mg) has been met as per results published in The Journal of Rheumatology.
    • 15 Dec 2016 Results published in The Journal of Rheumatology
    • 05 Nov 2015 Results published in a CymaBay Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top